Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant Therapy for Macular Edema: A Randomized Controlled Trial - PubMed
3 days ago
- #dexamethasone implant
- #combination therapy
- #macular edema
- Study compares efficacy and safety of conbercept monotherapy vs. conbercept combined with dexamethasone implant for macular edema (ME).
- 70 patients with ME secondary to diabetic retinopathy or retinal vein occlusion were randomized into monotherapy (36 eyes) or combination therapy (34 eyes) groups.
- Combination therapy showed greater improvement in best-corrected visual acuity (BCVA) by week 8 and greater reduction in central macular thickness (CMT) at weeks 4 and 8.
- Combination therapy required significantly fewer injections overall but had a higher incidence of ocular hypertension.
- Optical coherence tomography (OCT) biomarkers improved more substantially in the combination group during the first 12 weeks.
- Hard exudate (HE) was associated with poor visual prognosis.
- Conclusion: Conbercept combined with dexamethasone implant is efficient and safe, providing accelerated visual and anatomical improvements in the short term with fewer injections compared to monotherapy.